Stanford Medical Center
Palo Alto, California, 94304, United States
NCT Number: NCT06567574
The purpose of this study is to determine the accuracy of an AI-based tool in the prediction of postoperative delirium (POD), in a population at moderately high risk of developing this syndrome (i.e., elderly orthopedic subjects). The population to be studied has already been enrolled in a parallel study regarding the likelihood of developing delirium, its relationship to the type of anesthetic, and the relationship between anesthetic type, development of delirium and risk for post-operative cognitive impairment (including risk for dementia) (Protocol ID#55169 [David Drover-Principal investigator; José Maldonado-Co-investigator]).
Looking for future studies?
Notify Me65 year and older
All sexes
Observational
Palo Alto, California, 94304, United States
Study investigators would like to determine the real-life accuracy of a new tool developed for the prediction of delirium: Pre-Interventional Preventive Risk Assessment (PIPRA) Tool. The importance of assessing the risk for post-operative delirium (POD) includes: providing clinicians and patients with accurate predictive information regarding the patient's risk for developing delirium as part of the risk/benefit calculation for surgical procedures, and thus potential risk of subsequent cognitive impairment; as well as the ability to introduce timely prophylactic techniques that may prevent its onset.
The PIPRA tools consists of nine items commonly found in any presurgical patient's electronic medical record (EMR). The tool has been designed to run in the background of the EMR and automatically calculate the patient's risk for developing delirium upon admission for surgical intervention. For our study, we will be applying the PIPRA tool to the EMR of patients already enrolled in a parallel study as detailed above.
The PIPRA tool predicts the risk of developing POD delirium based on its algorithm that takes into consideration the following nine clinical variables: age, height/weight or body mass index, the American Society of Anesthesiologist physical status Classification system (ASA), past history of delirium, past history of cognitive impairment (including dementia), number of medications, preoperative C-reactive protein levels, surgical risk (as determined by the European Society of Anesthesiology), and type of surgery. The subsequent result predicts the risk (in percentage) of a patient developing POD following surgery.
The PIPRA tool is fully integrated into EMR systems, operating in the background, extracting relevant information, and automatically generating a delirium prediction score. In addition, this software possesses the flexibility to recalibrate the delirium risk based on the availability of the nine clinical variables.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline measurement of variables and detection of delirium presenting up to 72 hours post-operatively
Assessment of the accuracy on the prediction of subjects identified as developing delirium by the PIPRA tool, as compared with post-operative standardized delirium assessment tools. We will compare the assessment of the PIPRA prediction tool (performed pre-op) with the actual development of delirium as assessed by a clinical assessment based on DSM; the CAM-ICU & SPTD assessment tools.
Time frame: Up to 72 hours post-operatively
Number of subjects diagnosed with post-operative delirium
Time frame: Up to 72 hours post-operatively.
For those who develop delirium, the phenotype of delirium will be determined as per the Liptzin-Levkoff Criteria (based on DSM diagnostic Criteria). As such, all delirium episodes will be categorized as: hyperactive, hypoactive, mixed, or subsyndromal delirium.
Time frame: Up to 10-year post-operatively.
Impact of delirium occurrence and emergence of cognitive impairment post-operatively
Time frame: Baseline measurement of variables and detection of delirium presenting up to 72 hours post-operatively
Sensitivity and specificity of various cut off points of the PIPRA tool for detecting postoperative delirium.
Time frame: Baseline measurement of variables and detection of delirium presenting up to 72 hours post-operatively
Receiver operating characteristic (ROC) curve analysis of PIPRA tool
Time frame: From date of post-operative admission up to time of postoperative discharge, an average of 72 hours.
Mortality rate immediately after index surgery
Time frame: From date of post-operative admission up to time of postoperative discharge (assessed up to 1 year after admission).
Total number of days admitted to the hospital
Time frame: Type of facility the patient was discharge to from the hospital (assessed up to 6 months from admission)
Site of discharge (e.g., home, rehabilitation, skilled nurse facility, etc)
Time frame: Time to discharge from the hospital (assessed up to 6 months from admission)
Need for admission to an intensive care unit due to clinical necessity or deterioration
Time frame: From post-operative hospital admission up to time of postoperative discharge (assessed up to 6 months from admission)
Need of pharmacological protocol for management of delirium
Stanford University
Other
Stanford Study of the Validation of the Pre-Interventional Preventive Risk Assessment (PIPRA) Tool In The At-Risk Orthopedic Surgery Population
Acronym: PIPRA-ORTHO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05209555
Cognition Disorders, Cognitive Dysfunction
Eindhoven, Netherlands
View Trial DetailsNCT06519890
Cognition Disorders, Cognitive Dysfunction
Palo Alto, California, United States
View Trial DetailsNCT05114876
Cognition Disorders, Cognitive Decline
Toronto, Ontario, Canada
View Trial DetailsNCT06150339
Behavior, Brain Diseases
Pickering, Ontario, Canada
View Trial Details